Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Genmab A/S reported updated Phase 2 trial data for petosemtamab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. The combination achieved a median overall survival of 28.2 months, an overall response rate of 63%, and a median progression-free survival of 9.0 months. The findings were presented at the ESMO Congress 2026. The company is also conducting four Phase 3 trials for petosemtamab in various cancer types.
How this was made
The 30-second read
Why it matters
The updated Phase 2 readout adds more mature follow-up and reports median OS reached with durable response estimates, potentially improving perceived probability of success for ongoing Phase 3 programs and any future partnering discussions.
Market read
Traders may adjust biotech risk exposure based on updated survival and response metrics from a key combination cohort, even without regulatory milestones.
What to watch
The article does not provide comparator arms, statistical significance, or subgroup efficacy detail beyond broad PD-L1/p16 activity, which may temper enthusiasm despite strong headline medians.
Background
Petosemtamab is an investigational IgG1 bispecific targeting EGFR and LGR5, being studied as monotherapy and with pembrolizumab across solid tumors, including multiple Phase 3 LiGeR trials.
Ticker impact
Genmab reported updated Phase 2 results for petosemtamab plus pembrolizumab, including median OS 28.2 months and ORR 63% in 1L r/m HNSCC.
Likely positive repricing as investors weigh improved survival and response durability versus ongoing Phase 3 read-through risk.
The article discloses specific, mature efficacy endpoints (median OS reached, ORR, mPFS, CR rate) plus safety details (no Grade 5, no treatment-related deaths), which can shift expectations for future trial outcomes and partnering potential.
Market effects
Reinforces investor appetite for EGFR/LGR5-targeting bispecific oncology strategies and PD-1 combination regimens.
Primarily impacts European biotech sentiment around ESMO readouts; limited direct macro linkage.
Could modestly influence global oncology biotech risk appetite if the data is viewed as competitive versus existing PD-1 combinations.
Counterpoint
Phase 2 results may not translate into Phase 3 success; investors could fade the move if endpoints are not statistically definitive or if patient selection limits generalizability.
Key entities
- companyGenmab A/S
Sponsor of the petosemtamab Phase 2 trial in combination with pembrolizumab for first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma.
- drug_candidatepetosemtamab
Investigational EGFR/LGR5 IgG1 bispecific antibody evaluated in combination with pembrolizumab.
- drugpembrolizumab
PD-1 inhibitor used in the combination arm.
- eventESMO Congress 2026
Conference where the updated Phase 2 data were presented.
